Surveillance colonoscopy at five years was non-inferior to three after high-risk adenomas

The edition in brief

In EPoS II, 10,799 European patients with high-risk adenomas removed were randomised to first surveillance colonoscopy at 3 or 5 years. At a 5.5-year interim analysis, colorectal cancer incidence was 0.82% versus 0.77%, meeting non-inferiority; colorectal cancer deaths were 2 and 3. In EXCALIBER-RRMM, iberdomide with daratumumab and dexamethasone produced MRD-negative complete response in 41% versus 21% with daratumumab, bortezomib and dexamethasone in relapsed myeloma after one or two prior lines, but grade 3–4 neutropenia (84% vs 11%), infection (39% vs 22%) and pneumonia were more common; progression-free survival is not yet reported. In a phase 1–2 study, the oral RAS(ON) inhibitor daraxonrasib produced responses in 31–37% of 136 previously treated patients with RAS-mutant NSCLC, with grade 3 or higher adverse events in 54%. An analysis of IQVIA data from 71 countries found essential cancer medicines requiring complex genomic tests had about 65% lower uptake, lowest in lower-income countries. And a meta-analysis of four observational studies linked androgen deprivation therapy with higher odds of acute kidney injury (OR 1.34).